PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Eutilex, an immuno-oncology pipeline developer, is contesting a KRX delisting decision from July 2026 via injunction while trading remains suspended, compounded by an ownership dispute and deepening capital erosion.
The company is contesting KRX's July 2026 delisting decision with an injunction; trading remains suspended
Court rehabilitation proceedings opened in March 2026 were ended by a termination decision in June 2026
Since the founder's full stake sale in December 2025, an ownership dispute and mutual criminal complaints have continued
Total equity has declined for four straight years, with the 2025 debt ratio surging to 161%
AstraZeneca's discontinuation of its rival program has drawn relative attention to EU307's competitive position
Founded in 2015 and listed on KOSDAQ in 2018 through the technology special listing track, Eutilex is an immuno-oncology developer built on three platforms: T-cell therapy, CAR-T cell therapy, and antibody therapeutics.
Its core pipeline includes EU307, a fourth-generation CAR-T therapy targeting solid tumors such as hepatocellular carcinoma, and EU103, an antibody therapy that converts tumor-associated M2 macrophages into M1 macrophages to induce an immune response; both received Phase 1 IND approval from Korea's Ministry of Food and Drug Safety in 2023 and remain in Phase 1 trials.
The pipeline also includes the 4-1BB antibody EU101 and the T-cell therapy EU204 for lymphoma and solid tumors. Having generated little revenue for most of its listed history, the company secured its first meaningful top line after acquiring healthcare data management firm IncSystem in the second quarter of 2024.
In the competitive landscape for GPC3-targeted CAR-T therapies for solid tumors, the number of candidates with disclosed clinical data narrowed to four, including EU307, after AstraZeneca discontinued its own candidate AZD5851; none of the remaining candidates have yet entered Phase 2.
In December 2025, founder Kwon Byung-se sold his entire 10.98% stake to Cheongan Investment for 10 billion won, triggering a change in the largest shareholder.
However, a subsequent dispute erupted after Cheongan Investment's Jeong In-gu, who had been appointed as management delegate, was dismissed, leading both sides to file mutual criminal complaints for breach of trust.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.3B | -₩5.2B | −224.4% |
| 2025Q3 | ₩3.5B | -₩3.8B | −108.6% |
| 2025Q4 | ₩2.4B | -₩5B | −210.5% |
| 2026Q1 | ₩1.3B | -₩2.6B | −206.7% |
| 2026Q2 | ₩500M | -₩2.2B | −402.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩200M | -₩36.7B | -₩34.5B | −17032.8% | −39.3% | 15.0% |
| 2023 | ₩100M | -₩29.8B | -₩27.7B | −22622.8% | −45.9% | 15.0% |
| 2024 | ₩9.5B | -₩26.5B | -₩29.2B | −278.3% | −73.0% | 56.6% |
| 2025 | ₩10.3B | -₩18.9B | -₩23.9B | −183.8% | −156.6% | 161.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Eutilex has posted operating and net losses for four consecutive years from 2022 through 2025. Annual operating losses were 36.73 billion won in 2022, 29.78 billion won in 2023, 26.51 billion won in 2024, and 18.92 billion won in 2025, showing three straight years of narrowing losses.
Net losses attributable to owners fluctuated but also eased overall, from 34.47 billion won in 2022 to 27.72 billion won in 2023, 29.17 billion won in 2024, and 23.92 billion won in 2025.
Following the IncSystem acquisition, revenue rose to 9.53 billion won in 2024 and 10.29 billion won in 2025, lifting the operating margin from extreme negative levels of -22,622.8% in 2023 and -17,032.8% in 2022 to -278.3% in 2024 and -183.8% in 2025, though operating losses still run at nearly double revenue.
On a quarterly basis, revenue of 3.53 billion won and an operating loss of 3.84 billion won in the third quarter of 2025 were followed by a sharp widening in the fourth quarter, with revenue of 2.39 billion won, an operating loss of 5.03 billion won, and an owners' net loss of 11.46 billion won.
In 2026, revenue fell quickly to 1.25 billion won in the first quarter and 0.53 billion won in the second quarter, with operating losses of 2.59 billion won and 2.15 billion won, respectively.
The sum of owners' net losses over the trailing four quarters (Q3 2025 through Q2 2026) reached 20.47 billion won, indicating that large-scale losses have persisted.
On the balance sheet, total equity fell for four consecutive years, from 90.87 billion won in 2022 to 63.20 billion won in 2023, 42.47 billion won in 2024, and 15.79 billion won in 2025, while the debt ratio surged from 15.0% in 2022-2023 to 56.6% in 2024 and 161.0% in 2025, signaling a heightened risk of capital erosion.
The immuno-oncology market, particularly CAR-T cell therapy, is at a stage where products already commercialized in hematologic cancers are being pushed to expand into solid tumor indications.
GPC3-targeted CAR-T therapies for solid tumors such as hepatocellular carcinoma remain in an early competitive phase with no candidate yet in Phase 2, with Baylor College of Medicine's IL15.CAR, Carl June's team at the University of Pennsylvania with huCART19-IL18, and Eutilex's EU307 cited as leading candidates.
AstraZeneca's decision to discontinue its GPC3 CAR-T candidate AZD5851, citing strategic portfolio prioritization, has reshaped the field by reducing the number of competing candidates.
Across Korea's broader biotech sector, funding conditions have become increasingly bifurcated, with capital flowing toward companies with proven licensing deals or clinical data while those with delayed progress struggle to secure new investors.
Financial regulators have been running a concentrated delisting management period since February 2026, tightening exit procedures for distressed listed companies and increasing the listing-maintenance burden on biotech firms with weak performance and audit opinion issues.
Against this backdrop, 42 KOSDAQ-listed companies triggered delisting grounds related to their fiscal 2025 audit reports, and Eutilex was among them.
The company's foremost challenge has shifted from clinical progress to the outcome of legal proceedings over whether it remains listed.
After the Korea Exchange issued a delisting decision on Eutilex's common shares on July 2, 2026, the company filed for an injunction to suspend the effect of that decision until a final court ruling, and trading has been halted since July 6, 2026, pending the court's determination.
Prior to that, trading had already been suspended since February 9, 2026, due to a listing eligibility review and delisting grounds tied to the fiscal 2025 audit opinion.
The company received a court rehabilitation opening decision from the Seoul Bankruptcy Court on March 30, 2026, with CEO Kwon Byung-se serving as custodian without a separately appointed administrator, but a subsequent disclosure confirms that the rehabilitation proceedings were later terminated by a dismissal decision.
Recent industry reporting also classified Eutilex, alongside companies such as Kainos Medicine, Celestra, and Olipass, as having already received a delisting decision and now pursuing injunctions and other legal remedies.
On the pipeline side, EU307 had previously targeted the completion of its Phase 1 trial by the end of 2024, but given the heightened corporate and listing uncertainty, it requires further confirmation whether clinical progress and data disclosure timelines are proceeding as originally planned.
An ownership dispute also continues between Cheongan Investment, which had secured largest-shareholder status, and management, involving mutual breach-of-trust complaints and board dismissals, suggesting that a stable governance structure will take more time to establish.
Eutilex shares have been suspended from trading since July 6, 2026, pending the court's review of the injunction against the Korea Exchange's delisting decision, and the price displayed on screen reflects the last traded level before the suspension.
As a result, market multiples such as the price-to-book ratio should be viewed with the understanding that they are calculated on a frozen price rather than live supply and demand.
Because total equity has continued to shrink over the past three years, the same multiple carries a different meaning than it would have when the capital base was thicker. The company has not paid a dividend in any of the past four fiscal years.
Ultimately, valuation metrics during the current trading suspension carry limited reference value until the company's listing status and capital structure improvement are settled.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
AstraZeneca discontinued its GPC3-targeted CAR-T candidate AZD5851 citing strategic portfolio prioritization, narrowing the number of candidates with disclosed clinical data to four, including EU307.
Since no candidate in this space has yet entered Phase 2, EU307, still in Phase 1, now sits in a relatively less crowded field. However, this reflects a competitor's exit rather than proven clinical superiority of Eutilex's own candidate.
Through the acquisition of healthcare data management firm IncSystem in the second quarter of 2024, the company secured a meaningful revenue base for the first time, improving the operating margin from -22,622.8% in 2023 to -183.8% in 2025. This revenue, however, comes from a peripheral business unrelated to the drug pipeline itself.
An ownership reset was attempted when founder Kwon Byung-se sold his entire stake and Cheongan Investment entered as a new investor. This could have opened the door for fresh capital and new management practices, but it instead led to a governance dispute that has yet to settle.
The Korea Exchange issued a delisting decision on Eutilex's common shares on July 2, 2026, and after the company filed an injunction against it, trading has been suspended since July 6, 2026, pending a court ruling.
Recent industry reporting also classified Eutilex among companies that have already received a delisting decision and are now pursuing injunctions and related legal proceedings.
Total equity fell for four straight years, from around 90.87 billion won in 2022 to 15.79 billion won in 2025, while the debt ratio jumped from 56.6% in 2024 to 161.0% in 2025, heightening the risk of capital erosion.
Operating cash flow also recorded large net outflows every year over the same period, making the business difficult to sustain without external funding.
After the founder's stake sale, a representative from the new largest shareholder was appointed as management delegate and then dismissed, prompting both sides to file mutual criminal complaints for breach of trust, along with an injunction contesting the dismissal's validity. This ownership dispute adds uncertainty to the company's decision-making and funding strategy.
The listing status hinges on the outcome of the court's review of the injunction against the Korea Exchange's delisting decision. If the injunction is denied, delisting procedures could resume, and even if granted, uncertainty persists until the underlying lawsuit is resolved.
Large operating and net losses have persisted for four consecutive years, with operating cash flow recording net outflows every year, meaning that if external funding is cut off, the company's viability as a going concern could be threatened. The decline in total equity and the sharp rise in the debt ratio underscore this risk.
A series of events—including the change in largest shareholder, mutual complaints over the appointment and dismissal of a management delegate, and the opening and termination of court rehabilitation proceedings—raises questions about management continuity.
Without a stabilized governance structure, attracting new investment or negotiating licensing deals could also be negatively affected.
How a Seoul court rules on the injunction against the Korea Exchange's July 2, 2026 delisting decision is the key variable determining whether trading resumes.
If disclosures normalize, third-quarter 2026 results should be checked to see whether the revenue and loss trends are continuing.
Prosecutorial investigation results could alter the trajectory of the ownership dispute and the stability of the largest shareholder.
Following the June 2026 termination of the rehabilitation proceedings, it is worth confirming whether the company pursues alternative funding, a sale, or M&A.
Disclosure of Phase 1 progress for the core pipeline would provide additional grounds for assessing the company's drug development capability.
Eutilex is a technology-listed biotech with an immuno-oncology pipeline that includes the GPC3-targeted CAR-T therapy EU307 and the VSIG4 antibody EU103, but as of 2026 the company's core issue has shifted from clinical progress to the legal proceedings and ownership dispute surrounding its delisting.
Annual revenue gained scale after the IncSystem acquisition, but operating and net losses have continued for four straight years, and total equity has steadily declined since 2022, sharply lifting the debt ratio.
The change in largest shareholder that began with the founder's full stake sale in December 2025 triggered an unstable sequence of events, including the dismissal of a management delegate, mutual criminal complaints, and the opening and subsequent termination of court rehabilitation proceedings.
Following the Korea Exchange's delisting decision in July 2026, the company responded with an injunction, and trading has remained suspended pending the outcome.
On the industry side, a competitor's exit has drawn relative attention to EU307's position, though this is a factor separate from the company's own clinical performance.
Investors will need to monitor the court's injunction ruling, the progress of the ownership dispute, and quarterly results if and when trading resumes.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.